2020
2D Germanane Derivative as a Vector for Overcoming Doxorubicin Resistance in Cancer Cells
FOJTŮ, Michaela, Jan BALVAN, Martina RAUDENSKÁ, Tomáš VIČAR, Jiří ŠTURALA et. al.Základní údaje
Originální název
2D Germanane Derivative as a Vector for Overcoming Doxorubicin Resistance in Cancer Cells
Autoři
FOJTŮ, Michaela (203 Česká republika), Jan BALVAN (203 Česká republika, domácí), Martina RAUDENSKÁ (203 Česká republika, domácí), Tomáš VIČAR (203 Česká republika, domácí), Jiří ŠTURALA (203 Česká republika), Zdeněk SOFER (203 Česká republika), Jan LUXA (203 Česká republika), Jan PLUTNAR (203 Česká republika), Michal MASAŘÍK (203 Česká republika, domácí) a Martin PUMERA (203 Česká republika, garant)
Vydání
Applied Materials Today, Amsterdam, Elsevier, 2020, 2352-9407
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
20501 Materials engineering
Stát vydavatele
Nizozemské království
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 10.041
Kód RIV
RIV/00216224:14110/20:00116361
Organizační jednotka
Lékařská fakulta
UT WoS
000598346500012
Klíčová slova anglicky
2D materials; 4-carboxybutylgermanane; germanane; targeted drug delivery; doxorubicin; ovarian cancer; drug resistance
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 2. 2021 14:42, Mgr. Tereza Miškechová
Anotace
V originále
Cancer resistance to chemotherapeutics is a common problem often encountered in the clinical setting, hampering greatly the conventional therapy of malignant diseases for several decades. No generally efficient mechanism solving this phenomenon was found so far. Cancer cells can adapt to a stress applied in the form of chemotherapeutics and become insensitive to their effects. Under such a selection pressure, the cancer cells acquire features helping them not only to survive the changes in the environment but also to further divide and to form secondary lesions. Therefore, besides developing novel chemotherapeutics, refining the drug delivery mechanisms of the conventional ones is absolutely crucial to defeat the cancer, so we can fully benefit from the effects these therapeutics offer. Here, we demonstrated enhanced delivery of doxorubicin (DOX) to a DOX-resistant ovarian cancer cell line using completely novel 2D material 4-carboxybutylgermanane (Ge-Bu-COOH). In our study, we present Ge-Bu-COOH as a drug carrier evincing high drug-loading efficiency, low cytotoxicity up to the concentration of 2.5 mu g/mL and no hemolysis. Simultaneously, binding DOX to Ge-Bu-COOH increases DOX accumulation in the DOXresistant cell lines. It leads to a significant anticancer efficiency enhancement in A2780/ADR DOX-resistant cell line; with the maximal effect reaching up to 62.8% compared to free DOX. These findings have profound influence on understanding the behaviour of doxorubicin-resistant tumours and open new horizon to manage their treatment. (c) 2020 Elsevier Ltd. All rights reserved.